Clinical trials
Bronchiolitis Obliterans Syndrome trials in Italy
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
52 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2006 | 2 |
| 2007 | 1 |
| 2011 | 4 |
| 2012 | 2 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 5 |
| 2018 | 4 |
| 2019 | 2 |
| 2020 | 1 |
| 2021 | 2 |
| 2022 | 2 |
| 2024 | 3 |
| 2025 | 7 |
| 2026 | 3 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 27 |
| Recruiting | 11 |
| Active, not recruiting | 6 |
| Terminated | 4 |
| Unknown status | 3 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Incyte Corporation | 7 |
| Novartis Pharmaceuticals | 6 |
| Pharmacyclics LLC. | 3 |
| Fondazione IRCCS Policlinico San Matteo di Pavia | 2 |
| Gruppo Italiano Trapianto di Midollo Osseo | 2 |
| Pfizer | 2 |
| Sanofi | 2 |
| Abbott Medical Devices | 1 |
| AstraZeneca | 1 |
| Azienda Ospedaliera Brotzu | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Bronchiolitis Obliterans Syndrome | 52 |
| Leukemia | 9 |
| Graft vs Host Disease | 7 |
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 5 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 |
| Bone Marrow Diseases | 2 |
| Bronchiolitis Obliterans | 2 |
| Hematologic Diseases | 2 |
| Lymphoma | 2 |
| Lymphoma, Follicular | 2 |
Trials
Showing 51 to 52 of 52. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.